BCRX Stock Analysis: Buy, Sell, or Hold?
BCRX - BioCryst Pharmaceuticals Inc
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 13, 2026 at $9.87 · last confirmed Aug 17, 2026
Get Alerted When BCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
Interactive Price Chart (1 Month)
Loading historical data...
âšī¸ NEUTRAL: BCRX is fairly priced but lacks strong directional signals. At -12.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.
In-depth Analysis How we analyze
Technical Outlook: Technically, BCRX is in a uptrend. The price is currently testing key support at $9.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BCRX scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.82 (+118.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Protect Your Profits
Holding BCRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 118.0% below Wall St target ($20.82)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
Support & Resistance Levels
Fundamental Context
Data refreshes hourly during market hours. Next update: 7:32 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Is BCRX showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$653 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced BCRX Option Strategies
Professional options setups generated by AI based on today's BCRX price and gamma walls.
